RxDoctor Payments Data

Rick Neumeister, MD

Ophthalmology · Missoula, MTNPI 1003984303

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Glaukos Corporation at 51.2% of the total. Reporting peaked in 2019 at $72 and has fallen 61.5% since, to $28 in 2024. That places this record below the midpoint for ophthalmology clinicians in MT, where the typical reported total is $374.

$140in general payments, 2019–2025

Across 4 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$72
  • Alcon$51
  • AbbVie$17

What the payments were for

  • Food & beverage$140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Glaukos Corporation1$72
Alcon2$51
AbbVie1$17

How this compares

$140 in reported general payments places this provider in the 40th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$495,764
Medicare patients
1,077
Services billed
3,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine90$85,000
Cyclosporine49$23,115
Prednisolone Acetate222$11,529
RhopressaNetarsudil Mesylate22$10,184
RocklatanNetarsudil Mesylat/Latanoprost18$9,588
Ketorolac Tromethamine251$8,421
Brimonidine Tartrate45$6,346
LumiganBimatoprost21$6,331
Latanoprost289$4,426
MoxifloxacinMoxifloxacin Hcl184$3,824
Fluorometholone19$1,456
Timolol Maleate39$1,259
ErythromycinErythromycin Base92$911
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$777
Dorzolamide Hcl43$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$17$91,331111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 52 ophthalmology providers in Montana.

Other ophthalmology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →